Glaukos Corporation

3 days ago · fool.com

Glaukos raised its 2026 sales forecast to $775 million to $785 million and set a preliminary 2027 target of $1 billion, after third-quarter sales jumped 58% to $211.0 million. Profit is thinner than the adjusted figures suggest.

4 days ago · benzinga.com

Shares of Glaukos Corp (NYSE:GKOS) rose sharply in pre-market trading after the company reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

4 days ago · seekingalpha.com

Glaukos Corporation (GKOS) Q3 2026 Earnings Call Transcript

4 days ago · zacks.com

Glaukos (GKOS) came out with quarterly earnings of $0.47 per share, beating the Zacks Consensus Estimate of a loss of $0.12 per share. This compares to a loss of $0.16 per share a year ago.

4 days ago · zacks.com

The headline numbers for Glaukos (GKOS) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

4 days ago · marketbeat.com

Glaukos NYSE: GKOS reported record third-quarter consolidated net sales of $211 million, up 58% from the year-earlier period, led by growth in its Epioxa corneal health therapy and iDose TR glaucoma treatment. The company raised its full-year 2026 revenue outlook and introduced a preliminary target of $1 billion in revenue for 2027.

19 days ago · zacks.com

GKOS shares surge 36.8% in six months, fueled by strong sales, iDose TR and Epioxa expansion, higher guidance and promising clinical developments.

23 days ago · seekingalpha.com

Glaukos is transitioning from a single-product reimbursement story to a diversified ophthalmic pharmaceutical platform with two J-coded drugs and strong operating leverage. Q2 net sales grew 50% YoY to $185.6M, driven by iDose TR and the Epioxa launch, with non-GAAP gross margin reaching 85% and breakeven P&L. Management raised 2026 net sales guidance to $680–700M, with iDose TR sales expected at $275–280M and corneal health growth of 20%+.

24 days ago · zacks.com

GKOS expands its retinal pipeline with a licensing deal for RO-104 and exclusive RevMod platform rights, even as shares decline 6.3% following the news.

24 days ago · benzinga.com

Ophthalmic pharmaceutical and medical technology firm Glaukos Corporation (NYSE:GKOS) reported successful topline outcomes from its latest Phase 4 clinical study.